PL3268391T3 - Sposoby zmniejszania poziomów środków zawierających Fc w surowicy z zastosowaniem antagonistów FcRn - Google Patents

Sposoby zmniejszania poziomów środków zawierających Fc w surowicy z zastosowaniem antagonistów FcRn

Info

Publication number
PL3268391T3
PL3268391T3 PL16719896T PL16719896T PL3268391T3 PL 3268391 T3 PL3268391 T3 PL 3268391T3 PL 16719896 T PL16719896 T PL 16719896T PL 16719896 T PL16719896 T PL 16719896T PL 3268391 T3 PL3268391 T3 PL 3268391T3
Authority
PL
Poland
Prior art keywords
antagonsits
fcrn
methods
serum levels
containing agents
Prior art date
Application number
PL16719896T
Other languages
English (en)
Polish (pl)
Inventor
Nicolas G.H. Ongenae
Torsten Dreier
Peter Ulrichts
Johannes De Haard
Christophe Blanchetot
Original Assignee
Argenx Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenx Bvba filed Critical Argenx Bvba
Publication of PL3268391T3 publication Critical patent/PL3268391T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL16719896T 2015-03-09 2016-03-08 Sposoby zmniejszania poziomów środków zawierających Fc w surowicy z zastosowaniem antagonistów FcRn PL3268391T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562130076P 2015-03-09 2015-03-09
EP16719896.9A EP3268391B1 (en) 2015-03-09 2016-03-08 Methods of reducing serum levels of fc-containing agents using fcrn antagonsits
PCT/IB2016/000398 WO2016142782A1 (en) 2015-03-09 2016-03-08 Methods of reducing serum levels of fc-containing agents using fcrn antagonsits

Publications (1)

Publication Number Publication Date
PL3268391T3 true PL3268391T3 (pl) 2022-01-03

Family

ID=55863122

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16719896T PL3268391T3 (pl) 2015-03-09 2016-03-08 Sposoby zmniejszania poziomów środków zawierających Fc w surowicy z zastosowaniem antagonistów FcRn

Country Status (19)

Country Link
US (1) US20160264669A1 (enExample)
EP (2) EP4006051A1 (enExample)
JP (6) JP2018509413A (enExample)
KR (1) KR102720769B1 (enExample)
AU (2) AU2016230827B2 (enExample)
CA (1) CA2978253A1 (enExample)
DK (1) DK3268391T3 (enExample)
EA (1) EA038178B1 (enExample)
ES (1) ES2882999T3 (enExample)
HU (1) HUE056775T2 (enExample)
IL (2) IL254403B (enExample)
LT (1) LT3268391T (enExample)
MX (2) MX386491B (enExample)
MY (1) MY188761A (enExample)
PL (1) PL3268391T3 (enExample)
PT (1) PT3268391T (enExample)
SG (2) SG10201908259WA (enExample)
WO (1) WO2016142782A1 (enExample)
ZA (1) ZA202109042B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106103476B (zh) 2013-12-24 2020-11-27 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
JP6853178B2 (ja) * 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
MX386491B (es) * 2015-03-09 2025-03-18 argenx BV Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
CN111315772A (zh) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 抗apoc3抗体及其使用方法
MA51032A (fr) * 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
JP7486437B2 (ja) 2018-06-08 2024-05-17 アルジェニクス ビーブイ 免疫性血小板減少症を治療する組成物及び方法
WO2020148336A1 (en) * 2019-01-16 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of agents capable of inducing lc3-associated phagocytosis for treating sustained inflammation in patients suffering from chronic liver disease
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
BR112021024632A2 (pt) * 2019-06-07 2022-01-18 Argenx Bvba Formulações farmacêuticas de inibidores de fcrn adequados para administração subcutânea
CN114466663B (zh) * 2019-07-25 2026-01-02 建新公司 以FcRn拮抗剂治疗抗体介导的障碍的方法
ES2992247T3 (es) 2020-01-08 2024-12-11 argenx BV Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
WO2021160116A1 (zh) * 2020-02-10 2021-08-19 北京拓界生物医药科技有限公司 抗FcRn抗体、其抗原结合片段及其医药用途
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CA3183153A1 (en) * 2020-06-17 2021-12-23 Christian HINDERER Compositions and methods for treatment of gene therapy patients
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
CN117693523A (zh) * 2021-08-13 2024-03-12 舒泰神（北京）生物制药股份有限公司 特异性识别fcrn的抗体及其用途
KR20250037789A (ko) 2022-06-15 2025-03-18 아르젠엑스 비브이 Fcrn/항원-결합 분자 및 사용 방법
IL320846A (en) * 2022-11-14 2025-07-01 argenx BV Fcrn antagonist molecules and methods of use thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6128119A (en) 1997-01-10 2000-10-03 Asahi Kogaku Kogyo Kabushiki Kaisha Beam shaping optical system
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2002043658A2 (en) 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
EP1370288B1 (en) 2000-11-20 2012-01-11 Canadian Blood Services Method for treating thrombocytopenia with monoclonal ivig
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2487932A1 (en) 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
ATE480562T1 (de) 2002-10-15 2010-09-15 Facet Biotech Corp Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004204817C1 (en) 2003-01-13 2011-01-20 Macrogenics, Inc. Soluble FcyR fusion proteins and methods of use thereof
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
CN103755808B (zh) * 2009-03-25 2016-02-10 霍夫曼-拉罗奇有限公司 抗-α5β1抗体及其应用
US9067997B2 (en) * 2011-05-25 2015-06-30 Innate Pharma Sa Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders
US9790280B2 (en) * 2011-10-26 2017-10-17 Elanco Tiergesundheit Ag Monoclonal canine CD20 antibodies and methods of use
EP2780463A4 (en) * 2011-11-18 2015-07-01 Merck Sharp & Dohme FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING
CN104619722B (zh) * 2012-06-22 2022-10-04 达特茅斯大学理事会 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
CN106103476B (zh) * 2013-12-24 2020-11-27 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
MX386491B (es) * 2015-03-09 2025-03-18 argenx BV Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.

Also Published As

Publication number Publication date
JP7050191B2 (ja) 2022-04-07
JP7403575B2 (ja) 2023-12-22
MX386491B (es) 2025-03-18
EP3268391B1 (en) 2021-08-11
AU2016230827A1 (en) 2017-08-24
AU2016230827B2 (en) 2021-10-28
AU2021277720A1 (en) 2021-12-23
BR112017019191A2 (pt) 2018-05-02
NZ734416A (en) 2024-12-20
SG10201908259WA (en) 2019-10-30
MX2021011633A (es) 2021-10-22
HUE056775T2 (hu) 2022-03-28
JP2018509413A (ja) 2018-04-05
IL254403B (en) 2022-09-01
AU2021277720B2 (en) 2025-03-27
JP7391132B2 (ja) 2023-12-04
US20160264669A1 (en) 2016-09-15
EA201791984A1 (ru) 2017-12-29
LT3268391T (lt) 2021-09-10
PT3268391T (pt) 2021-08-19
EP4006051A1 (en) 2022-06-01
ZA202109042B (en) 2025-01-29
ES2882999T3 (es) 2021-12-03
JP2022105084A (ja) 2022-07-12
KR102720769B1 (ko) 2024-10-22
SG11201707053SA (en) 2017-09-28
JP7823011B2 (ja) 2026-03-03
EA038178B1 (ru) 2021-07-20
IL295425A (en) 2022-10-01
WO2016142782A1 (en) 2016-09-15
MX2017011534A (es) 2018-04-10
IL254403A0 (en) 2017-11-30
JP2022084868A (ja) 2022-06-07
DK3268391T3 (da) 2021-09-13
KR20170131463A (ko) 2017-11-29
JP2026012786A (ja) 2026-01-27
CA2978253A1 (en) 2016-09-15
JP2021073282A (ja) 2021-05-13
MY188761A (en) 2021-12-29
JP2024037846A (ja) 2024-03-19
EP3268391A1 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
IL254403A0 (en) Methods for lowering the amount of fc-containing substances in the serum by using fcrn antibodies
IL252837B (en) fcrn antibodies and methods of using them
LT3368688T (lt) Kompozicijos ir būdai, skirti modifikuotų citozinų nustatymui sekvenavimu
IL255406A0 (en) A method for growing in the culture of Acramansia
SMT202400004T1 (it) Anticorpi fcrn e loro metodi di utilizzo
HUE049094T2 (hu) Sejtmentes DNS kvantifikálási módszerei
EP3297661A4 (en) Method of improving characteristics of proteins
GB201515557D0 (en) Method of sequencing
IL254883A0 (en) A method for protein purification
IL249729A0 (en) Methods and materials for cleaning proteins
GB201515558D0 (en) Method of sequencing
IL254765A0 (en) A method for the monomerization of recombinant antibody molecules
PL3189336T3 (pl) Sposób określania ryzyka stanu przedrzucawkowego
IL255094A0 (en) A method for increasing the percentage of multimeric strains for a monomeric dsfv-fab antibody
GB201522552D0 (en) Method of improving adhesion
GB201904142D0 (en) Improved method of FT-IMS
SG11201800894SA (en) Method for parallel quantification of protein variant
IL252712A0 (en) Method for protein production
TH1601002706A (th) แอนทิบอดีที่จำเพาะต่อ FcRn
GB201611950D0 (en) Construction panel and method for its manufacture